Dr. Reddy’s, TR-Pharm to collaborate on 3 biosimilars in Turkey

pharmafile | March 11, 2016 | News story | Manufacturing and Production, Medical Communications, Sales and Marketing Dr Reddy's Laboratories, TR-Pharm, biosimilar, generics, marketing collaboration 

Three biosimilar products by the Indian generics company Dr. Reddy’s will be marketed by TR-Pharm in Turkey, the companies said Friday.  

No financial details were disclosed.

The companies, in a joint statement said, TR-Pharm will also manufacture the drug substance and drug product upon completion of its facility investment.

Mehmet Göker, General Manager of TR-Pharm, said: “Biosimilars are a key component of our investment strategy in Turkey to establish biotechnological API production for national use and regional exports. This agreement will not only enable more affordable medication but also support our research and development initiatives by building expertise within the country.”

The partnership will enable Dr. Reddy’s to widen the global footprint of its biosimilar business. The collaboration will be an important component of TR-Pharm’s ongoing biological product development and manufacturing business in the region.

M V Ramana, executive vice president & head branded markets (India and Emerging countries), said: “Turkey is a key emerging market and we are pleased to partner with TR-Pharm to ensure that patients in the region get access to our portfolio of high quality biosimilar products. Dr. Reddy’s Laboratories is and remains committed to providing access to affordable and innovative drugs to populations around the world, and this partnership will make this happen in Turkey.”

Anjali Shukla

Related Content

NICE release new guidance on rheumatoid arthritis treatment

NICE has today published final draft guidance for the treatment of moderate rheumatoid arthritis in …


Celltrion’s Humira biosimilar is comparable in treating rheumatoid arthritis

Celltrion has revealed new Phase 3 data demonstrating that its high concentration (100mg/mL) and citrate-free …


China approves its first biosimilar of Roche’s Herceptin in HER2+ cancers

China’s National Medical Products Administration (NMPA) has given the green light to Shanghai’s Henlius for …

Latest content